Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Moleculin Biotech ( (MBRX) ).
On March 23, 2026, Moleculin Biotech announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial of AnnAraC, a combination of Annamycin and cytarabine, for adults with relapsed or refractory acute myeloid leukemia. This marks the trigger point for interim data unblinding planned for mid-2026, which the company views as a potentially defining moment for assessing Annamycin’s prospects.
The ongoing global MIRACLE study, which continues to enroll toward 90 subjects, is designed with an adaptive Phase 2B/3 structure to streamline a potential registration pathway. Early blinded data from February 2026 showed a 40% composite remission rate in the first 30 patients in a high-risk population, reinforcing expectations that the mid-2026 readout could materially influence Moleculin’s development strategy and positioning in AML treatment.
The most recent analyst rating on (MBRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these somewhat are positive corporate developments (clinical progress, IP, and regained Nasdaq compliance), while valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline in development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, alongside additional oncology and antiviral programs.
Average Trading Volume: 179,773
Technical Sentiment Signal: Sell
Current Market Cap: $10.99M
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.